Vigil Neuroscience
Part of Sanofi
CompanyUnited States
Vigil Neuroscience develops one asset, in phase 1 (VG-3927 in Alzheimer's disease). Mostly small molecule acting on TREM2; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- Raised
- $420M
- 1
- Trial
- 2
- Signals
Pipeline
1Activates TREM2 signaling in microglia to promote their protective functions.
Phase 1, Small molecule, TREM2, Alzheimer's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Funding rounds and grants8
- Deals4
- Signals2
- Similar companies6